Halozyme Therapeutics, Inc.
NASDAQ:HALO · NASDAQ Global Select
+$0.56 today
Vol 3.34M · Avg 1.63M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:HALO · Revenue to Net Income
Key Ratios
Analysis
$1.5B of revenue converted into $348.8M of net income for the selected period. Gross margin is 77.1% and net margin is 27.2%, showing how much revenue survives after costs and taxes. EPS is $2.78, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B +37.6% | $1.0B +22.4% | $829.3M +25.6% | $660.1M +48.9% | $443.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $305.4M +91.6% | $159.4M -17.1% | $192.4M +38.1% | $139.3M +71.1% | $81.4M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $1.1B +27.5% | $855.9M +34.4% | $636.9M +22.3% | $520.8M +43.9% | $361.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 78.1% -6.2pp | 84.3% +7.5pp | 76.8% -2.1pp | 78.9% -2.7pp | 81.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $81.5M +3.1% | $79.0M +3.5% | $76.4M +14.6% | $66.6M +86.7% | $35.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $193.4M +25.3% | $154.3M +3.5% | $149.2M +3.9% | $143.5M +185.2% | $50.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $274.9M -9.7% | $304.4M +1.7% | $299.3M +18.2% | $253.3M +194.5% | $86.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $88.1M +8.3% | $81.3M -4.2% | $84.9M +70.9% | $49.6M +1556.4% | $3.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $573.1M -12.7% | $656.5M +45.3% | $451.9M +43.2% | $315.5M +21.8% | $259.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 41.0% -23.6pp | 64.7% +10.2pp | 54.5% +6.7pp | 47.8% -10.6pp | 58.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | $816.3M +48.0% | $551.5M +63.4% | $337.6M +26.2% | $267.5M -3.0% | $275.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 58.4% +4.1pp | 54.3% +13.6pp | 40.7% +0.2pp | 40.5% -21.7pp | 62.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $18.1M +0.2% | $18.1M -3.6% | $18.8M +10.7% | $16.9M +125.2% | $7.5M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$349.4M -6276.7% | $5.7M -47.4% | $10.8M +157.8% | -$18.6M +32.0% | -$27.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $466.9M -16.2% | $557.1M +59.9% | $348.3M +39.9% | $248.9M +0.2% | $248.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 33.4% -21.4pp | 54.9% +12.9pp | 42.0% +4.3pp | 37.7% -18.4pp | 56.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $150.0M +32.7% | $113.0M +69.4% | $66.7M +42.6% | $46.8M +130.3% | -$154.2M | $1.3B | -$1.6B | $745.2M |
| Net Income | $316.9M -28.6% | $444.1M +57.7% | $281.6M +39.3% | $202.1M -49.8% | $402.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | 22.7% -21.0pp | 43.7% +9.8pp | 34.0% +3.3pp | 30.6% -60.2pp | 90.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $3 -24.6% | $4 +64.3% | $2 +43.9% | $1 -48.3% | $3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $3 -25.4% | $3 +63.3% | $2 +45.8% | $1 -47.4% | $3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $119.8M -5.5% | $126.8M -3.9% | $131.9M -3.6% | $136.8M -2.7% | $140.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $123.9M -4.3% | $129.4M -3.6% | $134.2M -4.6% | $140.6M -4.2% | $146.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.26B
Cytokinetics, Incorporated
NASDAQ:CYTK
$9.72B
Henry Schein, Inc.
NASDAQ:HSIC
$9.11B
Corcept Therapeutics Incorporated
NASDAQ:CORT
$8.78B
AptarGroup, Inc.
NYSE:ATR
$7.66B
Merus N.V.
MRUS
$6.83B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.57B
Abivax S.A.
NASDAQ:ABVX
$6.57B
Grifols, S.A.
NASDAQ:GRFS
$6.31B
Caris Life Sciences, Inc.
NASDAQ:CAI
$5.05B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does HALO generate?
Halozyme Therapeutics, Inc. (HALO) reported $1.40B of revenue in fiscal 2025.
Is HALO profitable?
Halozyme Therapeutics, Inc. (HALO) reported $316.89M of net income, with a net margin of 22.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.